These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 31616641)

  • 41. Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.
    Ung N; Yang I
    J Neurooncol; 2015 Jul; 123(3):473-81. PubMed ID: 26070553
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [New therapeutic options in therapy of glioblastoma multiforme].
    Lakomý R; Burkon P; Burkonová D; Jancálek R
    Klin Onkol; 2010; 23(6):381-7. PubMed ID: 21351415
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Peptide vaccines for the treatment of glioblastoma.
    Swartz AM; Batich KA; Fecci PE; Sampson JH
    J Neurooncol; 2015 Jul; 123(3):433-40. PubMed ID: 25491947
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Repurposing antipsychotics as glioblastoma therapeutics: Potentials and challenges.
    Lee JK; Nam DH; Lee J
    Oncol Lett; 2016 Feb; 11(2):1281-1286. PubMed ID: 26893731
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of a multi-functional preclinical device for the treatment of glioblastoma.
    Metwally K; Bastiancich C; Correard F; Novell A; Fernandez S; Guillet B; Larrat B; Mensah S; Estève MA; Da Silva A
    Biomed Opt Express; 2021 Apr; 12(4):2264-2279. PubMed ID: 33996228
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Complexities of lysophospholipid signalling in glioblastoma.
    Ng W; Pébay A; Drummond K; Burgess A; Kaye AH; Morokoff A
    J Clin Neurosci; 2014 Jun; 21(6):893-8. PubMed ID: 24746442
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current Therapeutic Strategies for Glioblastoma.
    Rossignol J; Srinageshwar B; Dunbar GL
    Brain Sci; 2019 Dec; 10(1):. PubMed ID: 31888004
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nanotechnology for Treatment of Glioblastoma Multiforme.
    Michael JS; Lee BS; Zhang M; Yu JS
    J Transl Int Med; 2018 Sep; 6(3):128-133. PubMed ID: 30425948
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features.
    Karsy M; Gelbman M; Shah P; Balumbu O; Moy F; Arslan E
    Folia Neuropathol; 2012; 50(4):301-21. PubMed ID: 23319187
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
    Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
    Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.
    Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A
    J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nano-Therapies for Glioblastoma Treatment.
    Alphandéry E
    Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31963825
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reactive Astrocytes in Glioblastoma Multiforme.
    Guan X; Hasan MN; Maniar S; Jia W; Sun D
    Mol Neurobiol; 2018 Aug; 55(8):6927-6938. PubMed ID: 29363044
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme.
    Jindal V
    Mol Neurobiol; 2018 Nov; 55(11):8236-8242. PubMed ID: 29524050
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin.
    Katsetos CD; Dráberová E; Legido A; Dumontet C; Dráber P
    J Cell Physiol; 2009 Dec; 221(3):505-13. PubMed ID: 19650075
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Erlotinib: early clinical development in brain cancer.
    Addeo R; Zappavigna S; Parlato C; Caraglia M
    Expert Opin Investig Drugs; 2014 Jul; 23(7):1027-37. PubMed ID: 24836441
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies.
    Rao RD; Uhm JH; Krishnan S; James CD
    Front Biosci; 2003 May; 8():e270-80. PubMed ID: 12700121
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination therapy to checkmate Glioblastoma: clinical challenges and advances.
    Ghosh D; Nandi S; Bhattacharjee S
    Clin Transl Med; 2018 Oct; 7(1):33. PubMed ID: 30327965
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
    Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
    Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Emerging therapeutic targets and agents for glioblastoma migrating cells.
    Di C; Mattox AK; Harward S; Adamson C
    Anticancer Agents Med Chem; 2010 Sep; 10(7):543-55. PubMed ID: 20950259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.